



OPEN

## Long-term and daily use of molecular hydrogen induces reprogramming of liver metabolism in rats by modulating NADP/NADPH redox pathways

Yao Mawulikplimi Adzavon<sup>1,2,3</sup>, Fei Xie<sup>1,2,3</sup>, Yang Yi<sup>1,2</sup>, Xue Jiang<sup>1,2</sup>, Xiaokang Zhang<sup>1,2</sup>, Jin He<sup>1,2</sup>, Pengxiang Zhao<sup>1,2</sup>, Mengyu Liu<sup>1,2</sup>, Shiwen Ma<sup>1,2</sup> & Xuemei Ma<sup>1,2</sup>✉

Molecular hydrogen (H<sub>2</sub>) has emerged as a new therapeutic option in several diseases and is widely adopted by healthy people. However, molecular data to support therapeutic functions attributed to the biological activities of H<sub>2</sub> remain elusive. Here, using transcriptomic and metabolomic approaches coupled with biochemistry and micro-CT technics, we evaluated the effect of long-term (6 months) and daily use of H<sub>2</sub> on liver function. Rats exposed 2 h daily to H<sub>2</sub> either by drinking HRW (H<sub>2</sub> dissolved in H<sub>2</sub>O) or by breathing 4% H<sub>2</sub> gas showed reduced lipogenesis and enhanced lipolysis in the liver, which was associated with apparent loss of visceral fat and brown adipose tissue together with a reduced level of serum lipids. Both transcripts and metabolites enriched in H<sub>2</sub>-treated rats revealed alteration of amino acid metabolism pathways and activation of purine nucleotides and carbohydrate biosynthesis pathways. Analysis of the interaction network of genes and metabolites and correlation tests revealed that NADP is the central regulator of H<sub>2</sub> induced metabolic alterations in the liver, which was further confirmed by an increase in the level of components of metabolic pathways that require NADP as substrate. Evidence of immune response regulation activity was also observed in response to exposure to H<sub>2</sub>. This work is the first to provide metabolomic and transcriptomic data to uncover molecular targets for the effect of prolonged molecular hydrogen treatment on liver metabolism.

### Abbreviations

ALT	Alanine aminotransferase
TBA	Total bile acid
AST	Aspartate aminotransferase
HRW	Hydrogen-rich water
HI	Hydrogen inhalation
BAT	Brown adipose tissue
WAT	White adipose tissue mass
CTRL	Control

Molecular hydrogen (H<sub>2</sub>) is a tasteless and odorless gas and has demonstrated various biological and therapeutic effects on many diseases, from acute illnesses, including ischemia–reperfusion injury, to chronic diseases such as rheumatoid arthritis, neurodegenerative, and metabolic diseases<sup>1–3</sup>. H<sub>2</sub> is non-toxic even when used at high concentrations and rapidly crosses different tissue barriers, including blood–brain barriers, and penetrates various organelles<sup>4–6</sup>. H<sub>2</sub> interferes with reactive oxygen species (ROS) in living systems, a characteristic that supports its well-established antioxidant functions that lead to its frequent use to treat diseases associated with oxidative stress<sup>3,7,8</sup>.

<sup>1</sup>Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, People's Republic of China. <sup>2</sup>Beijing Molecular Hydrogen Research Center, Beijing 100124, People's Republic of China. <sup>3</sup>These authors contributed equally: Yao Mawulikplimi Adzavon and Fei Xie. ✉email: xmma@bjut.edu.cn

Molecular hydrogen is applied in therapeutics through various delivery routes, including hydrogen inhalation (HI), oral administration of hydrogen-rich water (HRW) or hydrogen tablets, and hydrogen-saturated saline injections. The concentration of H<sub>2</sub> in tissues after exogenous supply depends on the type of organ<sup>4</sup> and the H<sub>2</sub> delivery route<sup>9</sup>. Liver is the organ that accumulates more exogenous H<sub>2</sub><sup>4,9</sup>, which appears to significantly affect its homeostasis<sup>10</sup>. H<sub>2</sub> protected the liver against various acute and chronic injuries in animal models by suppressing excessive oxidative stress, inflammation, and cell death<sup>11,12</sup>. In addition to liver, preventive and therapeutic effects were obtained for H<sub>2</sub> in various animal experiments of disease models<sup>2,3</sup> and clinical trials in humans<sup>13–15</sup>. The preventive aspect of H<sub>2</sub> in disease models, its antioxidant effects<sup>7,8</sup>, its function in aging<sup>13,16</sup>, among many others<sup>17–19</sup>, are paving the way for the use of H<sub>2</sub> in healthy people to improve body performance or as a preventive therapeutic strategy.

In a recent clinical trial that was evaluated in a cohort of young and healthy people, the effects of inhaling 4% H<sub>2</sub> 20 min per day for 7 days on exercise performance revealed ergogenic properties such as improved running performance and torso strength<sup>20</sup>. Although Sim M. and colleagues had reported the beneficial effect of H<sub>2</sub> inhalation on the increase of the antioxidant and anti-inflammatory response in healthy adults<sup>21</sup>, other groups found that H<sub>2</sub> only reduced delayed-onset muscle soreness after running downhill<sup>22</sup> or improved muscle function during exercise without any effect on blood oxidative markers<sup>23</sup>. These data suggest that still little is known about H<sub>2</sub> performance under healthy conditions and therefore requires further research. As part of an effort to provide more data to help better understand the therapeutic functions attributed to the biological activities of H<sub>2</sub> in health conditions, our laboratory has initiated a study that evaluated the effect of long-term (6 months) hydrogen intervention on the physiological function of healthy rats<sup>24</sup>. The study found that H<sub>2</sub> induces a time-dependent alteration of different biochemical parameters, among which liver injury markers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bile acid (TBA) were significantly reduced in the serum of H<sub>2</sub>-treated rats<sup>24</sup>, suggesting that liver physiology and functions could be positively affected by prolonged exposure to H<sub>2</sub>. In the present study, we used transcriptomic and metabolomic approaches coupled with biochemistry and micro-CT techniques to access the global effects of long-term H<sub>2</sub> treatment on the liver and its relationship with body conditions.

## Materials and methods

**Animals and experimental design.** Three-week-old male Sprague-Dawley rats weighing 40–50 g were purchased from Vital River Laboratory Animal Technology Co., Ltd (Beijing, China). The animals were kept under standard conditions at 22 °C to 25 °C with a 12 h light–dark cycle and fed a normal diet. The animals were allowed to adapt to laboratory conditions one week before the experiment. Rats were randomly divided into three groups and treated with or without H<sub>2</sub> for six months. Rats in the control group (n = 6) were kept under normal conditions; rats in the HRW group (n = 6) were given access to HRW for 1 h, twice a day; In the HI group (n = 6), rats were exposed to 4% hydrogen gas for 1 h and twice a day. All procedures were approved by the Institutional Animal Experiment Committee of the Chinese People's Liberation Army (PLA) General Hospital and were carried out in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals (China) and the ARRIVE guidelines.

**Hydrogen-rich water preparation.** HRW (H<sub>2</sub> concentration > 800 μM) was kindly provided by Shenzhen Kelieng Biomedical Co. Ltd. (Shenzhen, China) and stored under atmospheric pressure at 23 ± 2 °C in a stainless-steel bucket (KLE-8). The hydrogen concentration was monitored using a hydrogen electrode (Unisense A/S, Aarhus, Denmark), ensuring that the hydrogen concentration of HRW for rats was maintained above 800 μM.

**Inhalation of hydrogen gas.** In the HI experiments, the rats were placed in breathing boxes (72 × 53 × 45 cm, length × width × height), where a gas mixture of 4% H<sub>2</sub> and 96% air containing 21% O<sub>2</sub> were delivered by an Oxy-Hydrogen Machine (SG-3000; Gang'an Health Management [Beijing] Co., Ltd., Beijing, China). The mixture was administered twice a day for 1 h each and, its composition was monitored using the Thermal trace GC ultragas chromatography (Thermo Fisher, MA, USA).

**Micro-computed tomography (micro-CT) analysis.** After anesthesia, rats were scanned by Quantum GX microCT (PerkinElmer) with voltage at 74 kV, view imaging at 72 × 40 mm, and pixel size at 72 μm. Subcutaneous and visceral fat mass was analyzed by the software (Analyze 12.0, PerkinElmer).

**Tissue and blood sampling.** Blood was sampled by eyeball blood collection early in the morning from overnight fasting rats. Serum was prepared by 20 min centrifugation at 1000 × g. Rats were then sacrificed by cervical dislocation, and the livers were harvested, snap-frozen in liquid nitrogen, and stored at – 80 °C until subsequent analysis. Intraabdominal perirenal (pWAT), epididymal (eWAT), subcutaneous inguinal (sWAT) white adipose tissue, and brown adipose tissue (BAT) were dissected and weighted.

**Biochemical analysis.** Serum total cholesterol, HDL-cholesterol (HDL-C), and LDL-cholesterol (LDL-C) were determined using commercially available kits (Nanjing Jiancheng Biochemistry, China) according to the manufacturer's instructions. The hormone-sensitive lipase (HSL) activity and the level of epinephrine in serum were evaluated using ELISA kits from MEIMIAN Industrial Co., Ltd. (Jiangsu, China).

**Transcriptomic analysis.** Total RNA was extracted from liver tissues with a standard Trizol RNA extraction procedure. RNA quality was assessed using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent, USA). Sequencing libraries were generated using the NEBNextR Ultra RNA Library Prep Kit for Illumina® (#E7530L, NEB, USA). The size of the library insert was tested using the Agilent Bioanalyzer 2100 system (Agilent, USA). The Bio-RAD CFX 96 fluorescent quantitative PCR instrument and Bio-RAD KIT iQ SYBR GRN were used to perform Q-PCR for accurate quantification of the effective concentration of the library (effective concentration of the library > 10 nM). After cluster generation, the libraries were sequenced by the Illumina NovaSeq 6000 S4 platform with paired-end reads by Annoroad Gene Technology (Beijing, China). Differential gene expression (DEGs) analysis was performed using the DESeq2R package version 1.16.3. and the DEGs were selected with  $|\text{LogFC}| > 1$  and  $\text{FDR} < 0.05$ .

**Untargeted metabolomics analysis.** The liver sample (50 mg) was homogenized in 500  $\mu\text{L}$  prechilled methanol, vortexed, and sonicated for 20 min on ice, incubated at  $-20^\circ\text{C}$  for 1 h, and centrifuged at 14,000 g for 20 min at  $4^\circ\text{C}$ . The extracted metabolites were concentrated by complete drying using a speedvac (Labconco, USA), redissolved in 100  $\mu\text{L}$  acetonitrile–water solution (1:1, v/v), and centrifuged at 14,000 g for 20 min at  $4^\circ\text{C}$ . The supernatant was sent to the Metabolomics Facility at Tsinghua University Branch of the China National Center for Protein Sciences (Beijing, China) and used for HPLC–MS or MS analysis. Untargeted metabolomics was performed using an ultra-performance liquid chromatography Q-Exactive Orbitrap mass spectrometer (UPLC Q-Exactive Orbitrap MS). The metabolomics data analysis and interpretation were performed with the MetaboAnalyst 5.0 web-based interface<sup>25</sup>. Significant metabolites were selected with  $|\text{FC}| \geq 1.5$  and  $p$  value  $< 0.05$ .

**Annotation and network analysis.** The WEB-based Gene Set Analysis Toolkit<sup>26</sup> and annotation and network analysis modules in MetaboAnalyst 5.0<sup>25</sup> were used to get biological insights of genes and metabolites differentially expressed, respectively. GraphPad Prism version 9.0.0 (121) was used to plot data and perform statistical analysis. One-way ANOVA with Tukey's post hoc test was used for error correction. Data were presented as the mean  $\pm$  SEM, and a  $p$  value  $< 0.05$  was considered significant.

## Results


**H<sub>2</sub> influences liver metabolism of lipids, carbohydrates, amino acids, and nucleic acids.** We recently found that H<sub>2</sub>-treated rats (HRW and HI) had reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bile acid (TBA)<sup>24</sup>, suggesting that prolonged exposure to H<sub>2</sub> could influence liver physiology and functions. To study the global effects of long-term H<sub>2</sub> treatment on the liver, we performed an RNA sequencing (RNA seq) analysis of liver tissues collected from untreated rats (Control group), rats given hydrogen-rich water (HRW) or inhaled 4% H<sub>2</sub> (HI) 2 h daily for 6 months (Fig. 1A, B). We identified from the liver transcriptome, 828 differentially expressed genes (DEGs): 321 in HRW versus CTRL, 435 in HI versus C, and 72 in HI versus HRW, of which there were 625 unique DEGs (Supplementary file 1). Profiling the expression of these 625 DEGs in all experimental groups showed three distinct expression clusters (Fig. 1B). The genes in cluster 1, down-regulated in the HRW and HI groups, are mainly involved in biological functions related to lipid metabolism and hormone synthesis; the genes in cluster 2, up-regulated by HRW and HI, play functions in cellular amino acid catabolic and carboxylic acid biosynthesis process; The cluster 3 regrouped genes enriched in immune system-related functions, and their expression appeared to be more specific to HI (Fig. 1B, Supplementary file 1). These data suggest that H<sub>2</sub> could also induce changes in liver immune functions in addition to its metabolic regulatory activities.

To further our understanding of the impact of H<sub>2</sub> on liver metabolism, we considered a comparative metabolomics approach that generates a profile of over 500 metabolites from various chemical classes. We observed a significant alteration in more than 100 metabolites, including organic acids, carbohydrates, nucleic acids, fatty acyls, and sterol lipids in the liver of H<sub>2</sub>-treated rats compared to untreated rats (Fig. 1C–E, Supplementary file 2). A closer inspection of the organic acid groups affected by H<sub>2</sub> treatment revealed a reduced level of amino acids such as L-serine, L-threonine, and Guanidineacetic acid, components of the glycine, serine and threonine metabolic pathways, and 4-Guanidinobutanoate and 4-Acetamidobutanoate, members of the arginine and proline metabolic pathways (Fig. 1F, G; Supplementary file 2).


The level of nucleoside diphosphate sugars, uridine 5'-diphosphogalactose and uridine 5'-diphosphoglucuronic acid, the two most common nucleotide sugar donors in animal cells<sup>27</sup> for the biosynthesis of polysaccharides, glycoproteins, and glycolipids<sup>28,29</sup>, was reduced, consistent with the increased level of carbohydrates observed in H<sub>2</sub> treated rats (Fig. 1I, P; Supplementary file 2). Rats treated with H<sub>2</sub> also showed an altered liver level of metabolites enriched in purine metabolism pathways. These rats had reduced levels of adenine (Fig. 1I), an increased level of deoxyadenosine and deoxyinosine (Fig. 1J, K), which, together with the unchanged liver content in uric acid and its reduced serum level (Supplementary Figure 1A, B), suggests that long-term exposure to H<sub>2</sub> may activate purine biosynthetic pathways.

Although long-term H<sub>2</sub> treatment induced a reduced level of fatty acyls and sterol lipids enriched in the biosynthesis pathways of lipids, bile acids, and steroid hormones (Fig. 1L, O; Supplementary file 2), it increases the level of acylcarnitines (Fig. 1M, N), fundamental players in the transport of organic acids and fatty acids from the cytoplasm to mitochondria<sup>30</sup> for oxidation to produce energy (Supplementary file 2). Furthermore, we note that H<sub>2</sub> treatment induced an increased level of acetoacetate (Fig. 1M), a ketone body produced from fatty acid oxidation<sup>30,31</sup> and previously reported to increase lipolysis and decrease lipid synthesis<sup>32</sup>, supporting the role of H<sub>2</sub> in promoting liver fatty acid oxidation.

Taken together, our data support the function of long-term use of H<sub>2</sub> in inducing lipolysis, amino acid catabolism to eventually support the pathways of biosynthesis of carbohydrates and purine nucleotides.



**Figure 1.** Long-term use of H<sub>2</sub> induces an alteration of metabolism in the liver of healthy rats. (A) Diagram of experimental design and sample processing methods. (B) Heatmap of the DEGs and biological process ontology term for the genes in each cluster. (C) Heatmap of metabolites significantly altered and an overview of the enriched metabolites sets for down (D) and up-regulated (E) metabolites in H<sub>2</sub> (HRW and HI) groups compared to control. (F–P) The expression level of metabolite differentially expressed compared to control ( $|FC| > 1.5$ ,  $p$  value  $< 0.05$ ) and significantly enriched in metabolites set with a  $p$  value  $< 0.05$ ; data are plotted as Mean  $\pm$  SEM, and their specific fold change (FC) and  $p$  value are detailed in supplementary file 2.



**Figure 2.** Change in body composition and serum biochemical parameters in response to long-term H<sub>2</sub> intervention. (A) Change in body weight and body fat composition measured by micro-CT (B). (C–D) Change in the volume of subcutaneous (green in panel B) and visceral fat (yellow in panel B) quantified by the Analyze12.0 software (PerkinElmer) from the micro-CT data. Mass of total WAT and BAT are presented in (E) and (F), respectively. Graphs in (G–J) summarize our previous finding of serum lipids of rats exposed to H<sub>2</sub> for 6 months<sup>24</sup>. The data of the level of epinephrine (L) in serum and the activity of HSL from rat liver lysates (K) are presented. Data are shown as Mean ± SEM. \**p* value < 0.05; \*\**p* value < 0.01; \*\*\**p* value < 0.001.

**H<sub>2</sub>-induced alteration of liver metabolism is accompanied by lipolysis.** Liver plays a central role in the regulation of metabolism and represents a communication bridge between organ systems<sup>33</sup>, suggesting that H<sub>2</sub>-induced alteration of liver metabolism could affect the whole-body metabolism and, therefore, body condition. To assess the effect of long-term use of H<sub>2</sub> on body composition, we measured the change in body weight (Fig. 2A) and fat mass (Fig. 2B–F) and change in serum metabolites (Fig. 2G–J). Long-term H<sub>2</sub> intervention reduced the body weight of rats in the HI group (455.20 ± 31.57 g), while no significant changes were observed in the HRW group (498.80 ± 18.50 g) compared to controls (525.00 ± 17.78 g) (Fig. 2A)<sup>24</sup>. Visceral fat volume (HRW: 7760 ± 429 mm<sup>3</sup>; HI: 6260 ± 1624 mm<sup>3</sup>; CTRL: 13,960 ± 4138 mm<sup>3</sup>) (Fig. 2B, C) and brown adipose tissue mass (BAT) (HRW: 0.54 ± 0.27 g; HI: 0.33 ± 0.10 g; CTRL: 0.63 ± 0.20) (Fig. 2F) were reduced in rats exposed to H<sub>2</sub>; white adipose tissue mass (WAT) (Fig. 2E) and subcutaneous fat (Fig. 2B, D) were unchanged. Although the total triglyceride level in serum was unchanged (Fig. 2J)<sup>24</sup>, we found the lipolytic stimulator epinephrine<sup>34,35</sup> (HI: 525.4 ± 42.40 pg/ml, HRW: 403.8 ± 62.48 pg/ml, CTRL: 335.4 ± 45.52 pg/ml) (Fig. 2L) and the hormone sensitive lipase HSL (HI: 279.90 ± 53.76 U/L vs. CTRL: 218.50 ± 22.28 U/L, *p* = 0.022) (Fig. 2K), high in serum and liver respectively of H<sub>2</sub> treated rats compared to control groups. These data, together with our previous report<sup>24</sup> on the decreased level of serum lipids, such as total cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), induced by long-term treatment with H<sub>2</sub> (Fig. 2G–I), showed that long-term exposure to H<sub>2</sub> could modulate body mass by affecting body fat composition.

**H<sub>2</sub> induces metabolic alteration in liver by modulating NADP/NADPH redox pathways.** To gain further insight into the mechanism associated with the reprogramming of liver metabolism by long-term H<sub>2</sub> intervention, we performed an interaction network analysis for genes and metabolites with a significant change in response to H<sub>2</sub> exposure. The analysis identified six subnets of genes encoding metabolic enzymes

and the corresponding metabolites (Fig. 3A, Supplementary file 3). NADP has the highest degree of node and connected metabolic enzyme-coding genes enriched in biological functions related to the metabolic process of lipids, amino acids, and carboxylic acids (Fig. 3B, C), the main alteration that we observed (Figs. 1, 2) during the H<sub>2</sub> intervention. Long-term H<sub>2</sub> intervention decreased the liver level of NADP (Fig. 3B, Supplementary Fig. 2) that was positively correlated with a reduced expression of genes coding for lipid and hormone metabolizing enzymes, while a negative correlation was observed for enzyme-coding genes involved in the metabolism of amino acids and carboxylic acids biosynthetic process (Fig. 3B). Knowing that the reduced form of NADP, NADPH provides high energy electrons for antioxidant defense and is necessary for nucleotide, amino acid, and lipid biosynthesis<sup>36,37</sup>, we hypothesized that the H<sub>2</sub>-induced decrease in the level of NADP would affect metabolic pathways that required NADP as the final acceptor of electrons. NADP and its reduced form NADPH are produced or consumed in the cell cytosol during reactions of cellular energy metabolism that involve glycolysis and the pentose phosphate pathway (PPP) and in the mitochondria during the tricarboxylic acid cycle (TCA)<sup>36–40</sup>. The NADP/NADPH pool can also be affected by metabolism reactions involving CYP450s that utilize NADPH as an electron donor<sup>41</sup>. Analysis of the effect of H<sub>2</sub> on the level of components of these metabolic pathways showed that H<sub>2</sub> treatment increased the level of metabolites such as G6P and 6PG (PPP) and malic acid (TCA cycle and cytosol) involved in reactions that reduced NADP to NADPH (Fig. 3D). However, the expression level of genes that encode cytochrome P450 oxidoreductases such as Cyp26b1, Cyp26a1, which lead to the accumulation of NADP, was found to be down-regulated after H<sub>2</sub> treatment (Fig. 3B). Together, these data suggest that H<sub>2</sub> induces reprogramming of liver metabolism through modulation of biological pathways that required NADP as an electron acceptor (reduction of NADP to NADPH).

## Discussion


The therapeutic potential of H<sub>2</sub> has been widely evaluated in various diseases<sup>1,2,5</sup> since 2007, when the first report showed the cytoprotective function of H<sub>2</sub> as an effective antioxidant that eliminated cytotoxic oxygen radicals<sup>7,42</sup>. Thousands of studies in different disease models ranging from acute to chronic diseases, including cancer, support the hypothesis that H<sub>2</sub> has a wide spectrum of activity. Unlike conventional drugs, a specific primary target has not yet been identified for H<sub>2</sub>, which would explain its broad efficacy in different diseases. H<sub>2</sub> showed great success in controlling various diseases<sup>1,2,5</sup> and is being evaluated for clinical applications in healthy people to improve performance and body condition<sup>13,20,23</sup>. However, it remains unknown how H<sub>2</sub> performs under healthy conditions. Therefore, this study aimed to fill this gap by providing molecular data to help further our understanding of the biological activities of H<sub>2</sub>.

As we previously reported, long-term H<sub>2</sub> intervention significantly affects physiological and biochemical parameters of healthy rats, with a significant alteration noted for liver biomarkers<sup>24</sup>. Moreover, no significant changes were observed for indicators of oxidative stress such as superoxide dismutase (SOD), catalase (CAT), and malondialdehyde (MDA) (Supplementary Figure 1C–E). Given that liver is the central and metabolic hub that connects most organs<sup>33</sup> and has the highest H<sub>2</sub> accumulation rate<sup>4,9</sup>, we have focused our study for this time on the molecular alteration in liver that can result from H<sub>2</sub> intervention. Furthermore, we have not observed any significant change for the global liver transcriptomes or metabolites between HRW and HI; therefore, the data in the present manuscripts are presented and discussed without any discrimination between the two H<sub>2</sub> groups.

Analysis of liver gene expression of healthy rats collected at the end of 6 months of H<sub>2</sub> intervention revealed a significant alteration of lipid metabolism pathways, confirming the observation of previous reports, which had shown the ability of H<sub>2</sub> to modulate lipid profile and functions<sup>43–45</sup>. Like in short-term studies of H<sub>2</sub> interventions, we have found long-term exposure to H<sub>2</sub> to reduce the serum level of total cholesterol<sup>24</sup>. This effect appears to be likely extended to other sterol lipids, as we observed a decrease in the level of several other sterol lipids, including glycocholic acid, ursodeoxycholic acid, turochenodeoxycholic acid, and corticosterone from the metabolomic study. The level of low-density lipoprotein cholesterol (LDL-C) was reduced, and no significant changes were observed for high-density lipoprotein cholesterol (HDL-C) in HRW-treated rats, consistent with previous observations<sup>24,43–45</sup>. Meanwhile, we found that HDL-C is significantly reduced by inhalation of H<sub>2</sub>. The biological relevance of this alteration would require further investigation, as HDL-C can sometimes become bad cholesterol and increase the risk of atherogenesis<sup>46–48</sup>. Our data, like others, confirmed that H<sub>2</sub> possesses lipid metabolic regulatory activities. Moreover, the absence of accumulation of lipids in the liver (Supplementary Fig. 3), as a consequence of the low serum cholesterol level, makes H<sub>2</sub> a relevant therapeutic option for people with disorders of lipid metabolism.

It is still unclear how H<sub>2</sub> fulfills the regulatory function of lipid metabolism. In the present study, we found that in addition to decreasing the level of serum and liver sterol lipids, long-term H<sub>2</sub> treatment reduced the level of liver fatty acyls by probably inducing their transport to mitochondria for oxidation, as evidenced by the increase in the level of mitochondrial fatty acid transporters, acylcarnitines. These results, together with the increase in the level of acetoacetate, a marker of ketogenesis in the liver<sup>30,31</sup>, suggest that H<sub>2</sub> induces oxidation of fatty acids and ketogenesis. Circulating epinephrine regulates the activity of hormone-sensitive lipase that controls the rate of ketogenesis<sup>31,34,35</sup>. Hormone-sensitive lipase is responsible for mobilizing free fatty acids from adipose tissues to serve as substrate for ketogenesis<sup>31,49,50</sup>. Considering the substantial loss of adipose tissue and the increased level of hormone-sensitive lipase and epinephrine in H<sub>2</sub>-treated rats, H<sub>2</sub> appears to promote lipolysis in adipose tissue, resulting in the release of free fatty acids which are transported and converted to ketone bodies in the hepatic mitochondria.

The transcriptional profile of rats treated with H<sub>2</sub> showed a significant up-regulation of genes enriched in the amino acid catabolic process, consistent with the reduced level of amino acids involved in the glycine, serine, and threonine metabolic pathways and the arginine and proline metabolic pathways. We also found that H<sub>2</sub> treated rats have purine nucleotides and carbohydrates biosynthesize pathways activated. Knowing that the main use



**Figure 3.** The implication of NADP/NADPH pathways in the metabolic regulatory functions of H<sub>2</sub>. **(A)** Genes and metabolites interaction network for differentially expressed genes and metabolites (genes and metabolites are shown in circles and squares, respectively). **(B)** Heatmap showing the expression profile of genes that encode metabolic enzymes connected to NADP. The coefficient (r) of the spearman correlation analysis is shown on the right of the heatmap. Data of statistically significant correlation results at a level of *p* value < 0.05 is shown in red. **(C)** Biological functions of genes that encode metabolic enzymes enriched in the NADP network. **(D)** Metabolic reaction of NADP/NADPH consumption and production pathways. The effect of H<sub>2</sub> on the level of components of these metabolic pathways is shown. Data are presented as Mean ± SEM. \**p* value < 0.05; \*\**p* value < 0.01; \*\*\**p* value < 0.001.

of amino acid breakdown is to provide building blocks for the synthesis of nitrogen-based compounds, protein synthesis, and as metabolic fuels<sup>51</sup>, it is possible that H<sub>2</sub> triggered the catabolism of these amino acids to support ketogenesis, nucleotide, and carbohydrates biosynthesis reactions.

Although a specific target has not yet been identified to support the therapeutic effects of H<sub>2</sub>, there is a consensus on its antioxidant properties. Cells respond to oxidative stress by modulating the redox system, which depends on the availability of reducing agents, including NADPH. NADP is essential for generating NADPH to provide the reduction power that maintains redox homeostasis and regulates cell metabolism<sup>36,37</sup>. In this study, we found that H<sub>2</sub> significantly decreases the level of NADP, which was accompanied by the activation of NADPH production pathways such as PPP. The level of NAD, which can also be generated by NADP dephosphorylation<sup>52,53</sup>, remained unchanged (Supplementary Figure 2), suggesting that H<sub>2</sub> induces NADP reduction into NADPH. Type 2 cytochrome P450s located in the endoplasmic reticulum use cytochrome P450 oxidoreductase (POR) as their redox partner. POR transfers electrons from NADPH to CYP450s in reactions that result in the generation of NADP<sup>41</sup>. In the present study, NADP levels decreased after H<sub>2</sub> treatment. Furthermore, the genes that encode differentially expressed POR enzymes and enzymes such as Hmgcs1, Hmgcr, Dhcr24 upstream of the Cyp51-dependent cholesterol synthesis pathway were negatively regulated, except for Cyp8b1, Cyp7b1, which are involved in cholesterol metabolism into bile acids<sup>54</sup>. The enzymatic activity of Hmgcr and CYP7A1 measured in liver homogenates from experimental rats, showed no significant differences (Supplementary Figure 4). Furthermore, analysis of the network of interaction of genes and metabolites connects NADP to metabolic pathways significantly affected by the long-term H<sub>2</sub> intervention. These findings indicate that H<sub>2</sub> must modulate biological pathways that involve the reduction of NADP to NADPH, and suggested that investigating biological pathways that require NADP as electron acceptors, such as PPP, could help identify the mechanisms to support the metabolic alteration observed in the liver during prolonged use of H<sub>2</sub>.

In conclusion, long-term use of H<sub>2</sub> appears to trigger lipid and amino acid catabolism in the liver to provide energy and building blocks for purine nucleotides and carbohydrates biosynthesis reactions by modulating pathways involving the redox couple NADP / NADPH. This study is the first to provide molecular data to help better understand the biological effect of H<sub>2</sub> on liver metabolism under healthy conditions. Furthermore, the significant impact of H<sub>2</sub> on lipid metabolism observed in this study provides a context to recommend its use in lipid metabolism disorders.

Received: 20 December 2021; Accepted: 22 February 2022

Published online: 10 March 2022

## References

1. Yang, M. *et al.* Hydrogen: A novel option in human disease treatment. *Oxid. Med. Cell. Longev.* **2020**, 8384742. <https://doi.org/10.1155/2020/8384742> (2020).
2. Ohta, S. Molecular hydrogen as a preventive and therapeutic medical gas: Initiation, development and potential of hydrogen medicine. *Pharmacol. Ther.* **144**, 1–11. <https://doi.org/10.1016/j.pharmthera.2014.04.006> (2014).
3. Ohta, S. In *Methods in Enzymology*, (eds. Cadenas, E. & Packer, L.) vol. 555, 289–317 (Academic Press, 2015).
4. Yamamoto, R., Homma, K., Suzuki, S., Sano, M. & Sasaki, J. Hydrogen gas distribution in organs after inhalation: Real-time monitoring of tissue hydrogen concentration in rat. *Sci. Rep.* **9**, 1255. <https://doi.org/10.1038/s41598-018-38180-4> (2019).
5. Huang, L. Molecular hydrogen: A therapeutic antioxidant and beyond. *Med. Gas Res.* **6**, 219–222. <https://doi.org/10.4103/2045-9912.196904> (2016).
6. Ohta, S. Recent progress toward hydrogen medicine: Potential of molecular hydrogen for preventive and therapeutic applications. *Curr. Pharm. Des.* **17**, 2241–2252. <https://doi.org/10.2174/138161211797052664> (2011).
7. Ohsawa, I. *et al.* Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat. Med.* **13**, 688–694. <https://doi.org/10.1038/nm1577> (2007).
8. Fukuda, K. *et al.* Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. *Biochem. Biophys. Res. Commun.* **361**, 670–674. <https://doi.org/10.1016/j.bbrc.2007.07.088> (2007).
9. Liu, C. *et al.* Estimation of the hydrogen concentration in rat tissue using an airtight tube following the administration of hydrogen via various routes. *Sci. Rep.* **4**, 5485. <https://doi.org/10.1038/srep05485> (2014).
10. Zhang, Y., Xu, J. & Yang, H. Hydrogen: An endogenous regulator of liver homeostasis. *Front. Pharmacol.* <https://doi.org/10.3389/fphar.2020.00877> (2020).
11. Yan, M. *et al.* Hydrogen gas inhalation attenuates sepsis-induced liver injury in a FUNDC1-dependent manner. *Int. Immunopharmacol.* **71**, 61–67. <https://doi.org/10.1016/j.intimp.2019.03.021> (2019).
12. Matsuno, N. *et al.* Beneficial effects of hydrogen gas on porcine liver reperfusion injury with use of total vascular exclusion and active venous bypass. *Transpl. Proc.* **46**, 1104–1106. <https://doi.org/10.1016/j.transproceed.2013.11.134> (2014).
13. Zanini, D. *et al.* The effects of 6-month hydrogen-rich water intake on molecular and phenotypic biomarkers of aging in older adults aged 70 years and over: A randomized controlled pilot trial. *Exp. Gerontol.* **155**, 111574. <https://doi.org/10.1016/j.exger.2021.111574> (2021).
14. Korovljev, D., Stajer, V., Ostojic, J., LeBaron, T. W. & Ostojic, S. M. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: A randomized controlled pilot trial. *Clin. Res. Hepatol. Gastroenterol.* **43**, 688–693. <https://doi.org/10.1016/j.clinre.2019.03.008> (2019).
15. LeBaron, T. W. *et al.* The effects of 24-week, high-concentration hydrogen-rich water on body composition, blood lipid profiles and inflammation biomarkers in men and women with metabolic syndrome: A randomized controlled trial. *Diabetes Metab. Syndr. Obes.* **13**, 889–896. <https://doi.org/10.2147/DMSO.S240122> (2020).
16. Liu, B. *et al.* Protective effect of molecular hydrogen following different routes of administration on D-galactose-induced aging mice. *J. Inflamm. Res.* **14**, 5541–5550. <https://doi.org/10.2147/jir.S332286> (2021).
17. Fransson, A. E., Videhult Pierre, P., Risling, M. & Laurell, G. F. E. Inhalation of molecular hydrogen, a rescue treatment for noise-induced hearing loss. *Front. Cell. Neurosci.* **15**, 658662. <https://doi.org/10.3389/fncel.2021.658662> (2021).
18. Fransson, A. E. *et al.* Hydrogen inhalation protects against ototoxicity induced by intravenous cisplatin in the Guinea pig. *Front. Cell. Neurosci.* **11**, 280. <https://doi.org/10.3389/fncel.2017.00280> (2017).
19. Kurrioka, T., Matsunobu, T., Satoh, Y., Niwa, K. & Shiotani, A. Inhaled hydrogen gas therapy for prevention of noise-induced hearing loss through reducing reactive oxygen species. *Neurosci. Res.* **89**, 69–74. <https://doi.org/10.1016/j.neures.2014.08.009> (2014).



20. Javorac, D., Stajer, V., Ratgeber, L., Betlehem, J. & Ostojic, S. Short-term H<sub>2</sub> inhalation improves running performance and torso strength in healthy adults. *Biol. Sport* **36**, 333–339. <https://doi.org/10.5114/biolsport.2019.88756> (2019).
21. Sim, M. *et al.* Hydrogen-rich water reduces inflammatory responses and prevents apoptosis of peripheral blood cells in healthy adults: A randomized, double-blind, controlled trial. *Sci. Rep.* **10**, 12130. <https://doi.org/10.1038/s41598-020-68930-2> (2020).
22. Kawamura, T. *et al.* Effects of hydrogen bathing on exercise-induced oxidative stress and delayed-onset muscle soreness. *Jpn. J. Phys. Fitness Sports Med.* **65**, 297–305. <https://doi.org/10.7600/jspfsm.65.297> (2016).
23. Aoki, K., Nakao, A., Adachi, T., Matsui, Y. & Miyakawa, S. Pilot study: Effects of drinking hydrogen-rich water on muscle fatigue caused by acute exercise in elite athletes. *Med. Gas Res.* **2**, 12. <https://doi.org/10.1186/2045-9912-2-12> (2012).
24. Xun, Z.-M. *et al.* Effects of long-term hydrogen intervention on the physiological function of rats. *Sci. Rep.* **10**, 18509. <https://doi.org/10.1038/s41598-020-75492-w> (2020).
25. Pang, Z. *et al.* MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. *Nucl. Acids Res.* **49**, W388–W396. <https://doi.org/10.1093/nar/gkab382> (2021).
26. Liao, Y., Wang, J., Jaehnic, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. *Nucl. Acids Res.* **47**, W199–W205. <https://doi.org/10.1093/nar/gkz401> (2019).
27. Freeze, H., Hart, G. & Schnaar, R. In *Essentials of Glycobiology [internet]* (eds. Varki, A., Cummings, R. D. & Esko, J. D.) (Cold Spring Harbor Laboratory Press, 2017).
28. Mohammad, M. A., Hadsell, D. L. & Haymond, M. W. Gene regulation of UDP-galactose synthesis and transport: Potential rate-limiting processes in initiation of milk production in humans. *Am. J. Physiol. Endocrinol. Metab.* **303**, E365–E376. <https://doi.org/10.1152/ajpendo.00175.2012> (2012).
29. Mikkola, S. Nucleotide sugars in chemistry and biology. *Molecules (Basel, Switzerland)* **25**, 5755. <https://doi.org/10.3390/molecules25235755> (2020).
30. Bhagavan, N. V. In *Medical Biochemistry*, 4th edn. (ed. Bhagavan, N. V.) 365–399 (Academic Press, 2002).
31. Laffel, L. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes. *Diabetes Metab. Res. Rev.* **15**, 412–426. [https://doi.org/10.1002/\(SICI\)1520-7560\(199911/12\)15:6<3c412::AID-DMRR72%3e3.0.CO;2-8](https://doi.org/10.1002/(SICI)1520-7560(199911/12)15:6<3c412::AID-DMRR72%3e3.0.CO;2-8) (1999).
32. Li, L. *et al.* Acetic acid influences BRL-3A cell lipid metabolism via the AMPK signalling pathway. *Cell. Physiol. Biochem.* **45**, 2021–2030. <https://doi.org/10.1159/000487980> (2018).
33. Priest, C. & Tontonoz, P. Inter-organ cross-talk in metabolic syndrome. *Nat. Metab.* **1**, 1177–1188. <https://doi.org/10.1038/s42255-019-0145-5> (2019).
34. Qvisth, V. *et al.* Human skeletal muscle lipolysis is more responsive to epinephrine than to norepinephrine stimulation in vivo. *J. Clin. Endocrinol. Metab.* **91**, 665–670. <https://doi.org/10.1210/jc.2005-0859> (2006).
35. Mora-Rodriguez, R. & Coyle, E. F. Effects of plasma epinephrine on fat metabolism during exercise: Interactions with exercise intensity. *Am. J. Physiol. Endocrinol. Metab.* **278**, E669–E676. <https://doi.org/10.1152/ajpendo.2000.278.4.E669> (2000).
36. Lunt, S. Y. & Van der Heiden, M. G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. *Annu. Rev. Cell Dev. Biol.* **27**, 441–464. <https://doi.org/10.1146/annurev-cellbio-092910-154237> (2011).
37. Van der Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. *Science* **324**, 1029–1033. <https://doi.org/10.1126/science.1160809> (2009).
38. Lewis, C. A. *et al.* Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. *Mol. Cell* **55**, 253–263. <https://doi.org/10.1016/j.molcel.2014.05.008> (2014).
39. Chen, L. *et al.* NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism. *Nat. Metab.* **1**, 404–415. <https://doi.org/10.1038/s42255-019-0043-x> (2019).
40. Jiang, P. *et al.* p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. *Nat. Cell Biol.* **13**, 310–316. <https://doi.org/10.1038/ncb2172> (2011).
41. Guengerich, F. P. Mechanisms of cytochrome P450-catalyzed oxidations. *ACS Catal.* **8**, 10964–10976. <https://doi.org/10.1021/acscatal.8b03401> (2018).
42. Wood, K. C. & Gladwin, M. T. The hydrogen highway to reperfusion therapy. *Nat. Med.* **13**, 673–674. <https://doi.org/10.1038/nm0607-673> (2007).
43. Zong, C. *et al.* Administration of hydrogen-saturated saline decreases plasma low-density lipoprotein cholesterol levels and improves high-density lipoprotein function in high-fat diet-fed hamsters. *Metab. Clin. Exp.* **61**, 794–800. <https://doi.org/10.1016/j.metabol.2011.10.014> (2012).
44. Song, G. *et al.* Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. *J. Lipid Res.* **54**, 1884–1893. <https://doi.org/10.1194/jlr.M036640> (2013).
45. Song, G. *et al.* Hydrogen activates ATP-binding cassette transporter A1-dependent efflux ex vivo and improves high-density lipoprotein function in patients with hypercholesterolemia: A double-blinded, randomized, and placebo-controlled trial. *J. Clin. Endocrinol. Metab.* **100**, 2724–2733. <https://doi.org/10.1210/jc.2015-1321> (2015).
46. Koizumi, J. *et al.* Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia. *Atherosclerosis* **58**, 175–186. [https://doi.org/10.1016/0021-9150\(85\)90064-4](https://doi.org/10.1016/0021-9150(85)90064-4) (1985).
47. Barter, P. & Genest, J. HDL cholesterol and ASCVD risk stratification: A debate. *Atherosclerosis* **283**, 7–12. <https://doi.org/10.1016/j.atherosclerosis.2019.01.001> (2019).
48. Rosenson, R. S. *et al.* Dysfunctional HDL and atherosclerotic cardiovascular disease. *Nat. Rev. Cardiol.* **13**, 48–60. <https://doi.org/10.1038/nrcardio.2015.124> (2016).
49. Kraemer, F. B. & Shen, W.-J. Hormone-sensitive lipase knockouts. *Nutr. Metab.* **3**, 12. <https://doi.org/10.1186/1743-7075-3-12> (2006).
50. Alves-Bezerra, M. & Cohen, D. E. Triglyceride metabolism in the liver. *Compr. Physiol.* **8**, 1–8. <https://doi.org/10.1002/cphy.c170012> (2017).
51. Newsholme, P., Stenson, L., Sulvucci, M., Sumayao, R. & Krause, M. In *Comprehensive Biotechnology*, 2nd edn. (ed. Moo-Young, M.) 3–14 (Academic Press, 2011).
52. Kawai, S. & Murata, K. Structure and function of NAD kinase and NADP phosphatase: Key enzymes that regulate the intracellular balance of NAD(H) and NADP(H). *Biosci. Biotechnol. Biochem.* **72**, 919–930. <https://doi.org/10.1271/bbb.70738> (2008).
53. Aglelal, L., Niere, M. & Ziegler, M. The phosphate makes a difference: Cellular functions of NADP. *Redox Rep.* **15**, 2–10. <https://doi.org/10.1179/174329210X12650506623122> (2010).
54. Debose-Boyd, R. A. A helping hand for cytochrome p450 enzymes. *Cell Metab.* **5**, 81–83. <https://doi.org/10.1016/j.cmet.2007.01.007> (2007).

## Author contributions

Y.M.A.: Investigation, Visualization, Formal analysis, Writing original draft; F.X.: Methodology, Investigation, Formal analysis, Writing original draft; X.M.: Conceptualization, Formal analysis, Writing—Review & Editing, Project administration, Funding acquisition; Y.Y., X.J., X.Z., J.H.: Investigation; P.Z., M.L. and S.M.: Writing—Review & Editing. All authors reviewed the manuscript.

## Funding

This work was supported by Military Logistics Key Open Research Projects (BHJ17L018).

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-07710-6>.

**Correspondence** and requests for materials should be addressed to X.M.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022